UK-Norwegian team to develop living skin equivalent testing model

Published: 20-May-2013
Research & Development Skin Care Pharmaceutical

For testing inflammatory responses


Epistem, a UK-based biotechnology and personalised medicine company has joined forces with Norwegian firm ScandiDerma to develop a new in vitro human living skin equivalent model for testing inflammatory responses.

The collaboration is made possible through the UK's Technology Strategy Board and Innovation Norway following a successful application for funding in the ‘Sustainable high value chemical manufacture through industrial biotechnology’ competition.

The project starts this month and runs to March 2014 and will take place at project leader Epistem's facilities in Manchester, UK and ScandiDerma's facilities in Barents Biocenter, Tromsø, Norway.

  • Companies:
  • Epistem
  • Innovate UK
See more

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

Read more
In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture

Trending Articles

  1. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  2. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  3. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  4. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Research & Development

Turntable-like catalytic reactor wins Innovate funding

The Spinning Disc Mesh Reactor developed by Bath chemical engineers aims to make pharmaceutical production safer and more sustainable
Media

Atelerix secures Innovate UK funding for cell transport tech

The funding will support the development of room temperature technologies for shipping therapeutic cells, as part of the company’s ‘BloodReady’ project
Ingredients

Research partnership removes bottleneck from AAV development

CPI, Cobra Biologics and GE Healthcare Life Sciences have developed a scalable, cost-effective purification process for adeno-associated viruses
Research & Development

UK government releases £125 million in grant funding to support innovators

The cash injection will see businesses turn ideas into new products and services on the market
Research & Development

Collaboration funds asthma diagnosis projects in the UK

Asthma UK and Innovate UK, have teamed up to fund three projects to help make diagnosis more accurate and treatment more efficient
Regulatory

Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industry

Global industry shows confidence in cell and gene therapies and in UK’s ability to deliver these life-changing products
Subscribe now